open access

Vol 62, No 5 (2011)
Original papers
Published online: 2011-11-08
Submitted: 2013-02-15
Get Citation

Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours

Anna Sowa-Staszczak, Dorota Pach, Jolanta Kunikowska, Leszek Krolicki, Agnieszka Stefanska, Monika Tomaszuk, Monika Buziak-Bereza, Renata Mikolajczak, Marta Matyja, Aleksandra Gilis-Januszewska, Agata Jabrocka-Hybel, Malgorzata Trofimiuk, Alicja Hubalewska-Dydejczyk
Endokrynologia Polska 2011;62(5):392-400.

open access

Vol 62, No 5 (2011)
Original papers
Published online: 2011-11-08
Submitted: 2013-02-15

Abstract

Background: The aim of this study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of the high affinity somatostatin receptor subtype 2 analogue, 90Y labelled Tyr3-octreotate, (90Y-DOTATATE) in neuroendocrine tumours (NETs).
Material and methods: 46 patients with disseminated or non-operable NET were enrolled in this study. The 90Y-DOTATATE therapeutic activity was calculated per total body surface area up to a total of 7.4 GBq/m2 administered in three to five cycles, repeated every four to nine weeks. Before and after the therapy, blood tests for haematology, kidney and liver function, and chromogranin A were performed.
Results: Out of 46 90Y-DOTATATE treated patients, one died before completing the therapy and 16 died after completing the therapy, among them one due to myocardial infarction. After 12 month follow-up, stabilisation of disease was observed in 47%, partial remission in 31%, and progression in 9% of the 45 patients who completed the therapy. Five patients died before completion of 12 months of follow-up. One of the patients died due to myocardial infarction. In one case, the information after 12 months is incomplete. The progression free survival was 37.4 months. During 12 months follow-up, transient decrease of PLT, WBC and haemoglobin values was observed. A transient increase of creatinine level (within normal ranges) and decrease of GFR values were found.
Conclusions: NETs 90Y-DOTATATE therapy results in symptomatic relief and tumour mass reduction. The mild critical organ toxicity does not limit the PRRT of NETs. (Pol J Endocrinol 2011; 62 (5): 392–400)

Abstract

Background: The aim of this study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of the high affinity somatostatin receptor subtype 2 analogue, 90Y labelled Tyr3-octreotate, (90Y-DOTATATE) in neuroendocrine tumours (NETs).
Material and methods: 46 patients with disseminated or non-operable NET were enrolled in this study. The 90Y-DOTATATE therapeutic activity was calculated per total body surface area up to a total of 7.4 GBq/m2 administered in three to five cycles, repeated every four to nine weeks. Before and after the therapy, blood tests for haematology, kidney and liver function, and chromogranin A were performed.
Results: Out of 46 90Y-DOTATATE treated patients, one died before completing the therapy and 16 died after completing the therapy, among them one due to myocardial infarction. After 12 month follow-up, stabilisation of disease was observed in 47%, partial remission in 31%, and progression in 9% of the 45 patients who completed the therapy. Five patients died before completion of 12 months of follow-up. One of the patients died due to myocardial infarction. In one case, the information after 12 months is incomplete. The progression free survival was 37.4 months. During 12 months follow-up, transient decrease of PLT, WBC and haemoglobin values was observed. A transient increase of creatinine level (within normal ranges) and decrease of GFR values were found.
Conclusions: NETs 90Y-DOTATATE therapy results in symptomatic relief and tumour mass reduction. The mild critical organ toxicity does not limit the PRRT of NETs. (Pol J Endocrinol 2011; 62 (5): 392–400)
Get Citation

Keywords

peptide receptor radionuclide therapy; neuroendocrine tumours; targeted therapy

About this article
Title

Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours

Journal

Endokrynologia Polska

Issue

Vol 62, No 5 (2011)

Pages

392-400

Published online

2011-11-08

Bibliographic record

Endokrynologia Polska 2011;62(5):392-400.

Keywords

peptide receptor radionuclide therapy
neuroendocrine tumours
targeted therapy

Authors

Anna Sowa-Staszczak
Dorota Pach
Jolanta Kunikowska
Leszek Krolicki
Agnieszka Stefanska
Monika Tomaszuk
Monika Buziak-Bereza
Renata Mikolajczak
Marta Matyja
Aleksandra Gilis-Januszewska
Agata Jabrocka-Hybel
Malgorzata Trofimiuk
Alicja Hubalewska-Dydejczyk

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl